Share Name Share Symbol Market Type Share ISIN Share Description
Cizzle Biotechnology Holdings Plc LSE:CIZ London Ordinary Share GB00BNG2VN02 ORD 0.01P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 1.40 299,223 08:00:00
Bid Price Offer Price High Price Low Price Open Price
1.35 1.45 1.40 1.40 1.40
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -3.96 4
Last Trade Time Trade Type Trade Size Trade Price Currency
16:07:51 O 34,546 1.423 GBX

Cizzle Biotechnology (CIZ) Latest News

More Cizzle Biotechnology News
Cizzle Biotechnology Investors    Cizzle Biotechnology Takeover Rumours

Cizzle Biotechnology (CIZ) Discussions and Chat

Cizzle Biotechnology Forums and Chat

Date Time Title Posts
05/7/202210:36Cizzle Biotechnology Holdings PLC819
21/6/202214:38Cizzle Biotech426

Add a New Thread

Cizzle Biotechnology (CIZ) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Cizzle Biotechnology trades in real-time

Cizzle Biotechnology (CIZ) Top Chat Posts

Cizzle Biotechnology Daily Update: Cizzle Biotechnology Holdings Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker CIZ. The last closing price for Cizzle Biotechnology was 1.40p.
Cizzle Biotechnology Holdings Plc has a 4 week average price of 1.35p and a 12 week average price of 1.35p.
The 1 year high share price is 7.25p while the 1 year low share price is currently 1.35p.
There are currently 278,447,788 shares in issue and the average daily traded volume is 2,224,322 shares. The market capitalisation of Cizzle Biotechnology Holdings Plc is £3,898,269.03.
mustau: 500k at what price or are you talking of £millions? This price is reflective of management, an mou means jack! We need real substance. I guess i'm peeved as I bought in much higher and nothing in the pot to add.
ddonaldson2: What seller? Lol, that comment alone makes me feel replying to you is a waste of time... Read back if interested, constant dumping of 500k shares which granted has stopped recently and the share price has stabilised, infact can't get a quote to buy the last few hours
ddonaldson2: Agreed what do you want them to do... they have been striking commercial agreements and expenses have been kept in check, I don't think the share price is down to poor management... Maybe more due to the seller
mirabeau: 'Last Thursday I was gobbing off at dinner to one of my guests, who has been a hugely successful fund manager, about Angle (AGL). To which he responded that Cizzle Biotechnology (CIZ) capitalised at just £5m was developing a method of early detection of lung cancer, particularly amongst the vast population of China where CIZ seems to have important trading links. CIZ is a spin off from York University. The full year results came out yesterday and are encouraging in the sense that there is no declaration of failure. However, cash is running out and a placing is surely inevitable. Faites vos jeux.' HTTP://
secretsqu: If Ciz are to meet their "anticipated" guidelines, then I would be hopeful to see the delivery of the immunoreagents to China sometime over the next 35 days.Caveat; anticipated.
dave4545: In the old days stocks like Ciz would have had a rub off effect from AGL but now everybody just piles in the stock with the news. I wonder how many have sold CIZ to actually buy AGL too
dave4545: If it rises 5-10% no good it will drift back. If it gets to 20-30% bingo then a momentum herd will pile in and this will be back at 2.8-3p in a few hours. You just have to look at Loop today, all time lows 6p and similar to Ciz with regular 2 way trade and any little rise getting sold into when it goes quiet and now bang out of nowhere up 130% today and everybody is trying to buy in even after this rise. If Ciz rose 100% more people would be buying than selling at 4p
dave4545: This tweet has sprung life into CIZ Cizzle Biotechnology plc @CizzlePlc · 11m With around 816,000 new lung #cancer cases diagnosed in #China in 2020 it's vital that #earlydetection of cancer is available to help save lives. With our #innovative research and technology, and our latest commercial agreement, we’re doing just that!
jigger_1: SSq - Latest TR1 just confirming CIZ RNS from 140222 ‘On completion of payment of the Initial Consideration, Conduit will hold 25,000,000 ordinary shares in Cizzle representing 8.98 per cent’
noirua: 3 February 2022 - Royalty Strategic Alliance for Early Lung Cancer Detection in China Cizzle Biotechnology, has signed a Memorandum of Understanding ("MOU") with the International Co-Innovation Centre for Advanced Medical Technology ("iCCAMT") and Shenzhen Intelliphecy Life Technologies Co., Ltd., announced on 25 November 2021, a full commercial agreement has now been executed to develop and market the Company's proprietary early lung cancer diagnostic tests in China. -- iCCAMT and Intelliphecy to fund all activities in China, including development, clinical trials, manufacture and distribution -- 10% royalty for the Company over all sales of products and services using CIZ1B in China -- Initial pilot of 300 patients planned The Agreement will generate future revenues for Cizzle Biotechnology via a 10% royalty on the sales of all products and services using its proprietary CIZ1B technology and from payment for monoclonal antibodies and reagents. The China partners will be solely responsible for funding all activities in China including development, clinical trials, manufacturing, and distribution. It is intended that initial development will commence within 60 days of Cizzle Biotechnology supplying its immunoreagents to the China partners, which is anticipated to be in Q2 2022. An initial pilot covering 300 patients is planned at China's premier cancer hospitals, which will allow for a true representative patient cohort to be included and, if successful, is expected to accelerate adoption and product rollout in China. "As reported in November 2021, when we signed our MOU with iCCAMT and Intelliphecy , lung cancer in China is a huge social and economic challenge, especially because of the difficulties in being able to detect it early enough to make clinical intervention effective. It is estimated that about 95.8 million people in China have a high risk of lung cancer and if screening was performed every three years, then more than 30 million tests per year would be required. At a target price of about GBP100 per test, the total available market for tests based on the CIZ1B biomarker would be GBP3 billion. (Frost & Sullivan estimates the market size in China is US$5.7 billion). We have already secured strong interest from our nationwide network of national clinical centers...
Cizzle Biotechnology share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Cizzle Bio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220706 21:52:12